HAN. CD109 is a potential biomarker for malignant tumors. American Journal of Translational Medicine, [S. l.], v. 4, n. 3, p. 111–121, 2020. Disponível em: https://ajtm.journals.publicknowledgeproject.org/index.php/ajtm/article/view/589. Acesso em: 2 may. 2024.